Cardiac Science Announces Second Quarter 2000 Results; $925,000 of Powerheart Hospital Bedside Defibrillator-Monitors Sold.

Business Editors & Health/Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--Aug. 14, 2000

Cardiac Science Inc. (OTCBB:DFIB), the developer of Powerheart(R), the only hospital monitor that provides life-saving defibrillation within seconds and without the aid of hospital staff, announced record revenue of $924,962 for the second quarter ended June 30, 2000, compared with no revenue for the same period in 1999.

Revenue for the quarter is attributed to the sale of 150 Powerheart bedside defibrillator-monitors and related proprietary disposable defibrillation electrodes. For the six-month period ending June 30, 2000, revenues totaled $1,549,604, compared with no revenues for same six-month period in 1999.

The company reported a second-quarter net loss of $2,796,621, or 23 cents a share. That compares with a net loss of $1,945,927, or 24 cents a share for the second quarter in 1999. For the six-month period ending June 30, 2000, the company reported a net loss of $5,516,151, or 44 cents a share, compared with a net loss of $3,104,088, or 40 cents a share, for the six months ended June 30, 1999.

Research and development expenses relating to the Automatic Defibrillation Module, a product currently under development, as well as costs for the Powerheart, totaled approximately $2,423,881, or 44 percent of the loss for the six-month period. Marketing expenses relating to the introduction and market launch of the Powerheart totaled approximately $1,826,466, or 33 percent of the loss year to date.

The Automatic Defibrillation Module(TM) utilizes the company's proprietary detection and defibrillation technologies, and is envisioned to be integrated into standard bedside patient monitors.

"We have achieved numerous milestones this year including selling 270 Powerhearts and saving two patient lives with Powerheart despite limited clinical use. Moreover, we secured $31 million in equity capital, licensed our technology to world's largest manufacturer of external defibrillators, Medtronic Physio-Control, and acquired wearable defibrillation technology in the Cadent transaction," said Raymond W. Cohen, president and chief executive officer of Cardiac Science.

"We plan to continue to invest in marketing programs to drive adoption of the Powerheart, as well as make significant expenditures to complete the development of our Automatic Defibrillation Module and wearable defibrillator product."

About Cardiac Science

Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary software that monitor and automatically treats cardiac arrest patients. RHYTHMx ECD(TM) tachyarrhythmia detection and defibrillation software, the company's core proprietary technology platform, has multiple applications including use in external defibrillators, wearable defibrillators and standard patient monitors that are widely used in hospitals throughout the world.

Powerheart, Cardiac Science's first commercial product, continuously monitors in-hospital patients at risk of sudden cardiac arrest, instantly detects the onset of a life-threatening heart rhythm, and when appropriate, automatically delivers defibrillation shocks within seconds and without human intervention to re-establish the heart's normal rhythm.

The ability to respond to a life-threatening heart rhythm within seconds saves lives and minimizes a loss of oxygen to the brain, thereby eliminating potential neurological damage and a diminished quality of life that often occurs when defibrillation is withheld for even a few minutes. Powerheart began shipping on Dec. 31, 1999, and is currently used in hospitals worldwide.

Cardiac Science's global sales network consists of prominent distributors in 41 countries encompassing Asia, the Middle East, Europe, South America and North America. The company has an exclusive agreement with Medtronic Physio-Control, a division of Medtronic Inc., the worldwide market leader in external defibrillator products, to distribute the Powerheart in the United States, Canada and nine European countries.

In June 2000, Cardiac Science licensed its proprietary technology to Medtronic Physio-Control, the world's largest manufacturer of external defibrillators, for integration into Medtronic Physio- Control's LIFEPAK(R) products for the hospital market. For more information, visit http://www.cardiacscience.com.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward-looking statements include, but are not limited to: the Powerheart's safety and efficacy, its ability to increase survival rates for in-hospital cardiac arrest victims, its ability to improve patient-care and lessen patient debilitation; the company's ability to successfully integrate its technology into Medtronic Physio-Control's LIFEPAK products; future expenditures for marketing and development; and applications of the company's technology. Cardiac Science cautions that these statements are qualified by various known and unknown factors that could cause actual results to differ materially from those reflected by the forward-looking statements. Such factors include, but are not limited to: future economic, regulatory and market conditions; future business decisions; market and clinical users' acceptance of new and existing products; impact of competitive products and pricing; and changing market conditions. Information on these and other factors are detailed in the company's Form 10-K for the year ending Dec. 31, 1999, and other documents filed with the Securities and Exchange Commission. The Powerheart and RHYTHMx ECD are a trademark of Cardiac Science Inc. LIFEPAK is a trademark of Medtronic Physio-Control.

                         Cardiac Science Inc.
             Consolidated Condensed Summary of Operations
                              (Unaudited)

                      Three Months Ended          Six Months Ended
                           June 30,                   June 30,
                      2000          1999         2000          1999

Sales           $    924,962  $         --  $  1,549,604  $         --

Net loss from
 operations     $ (2,808,522) $ (1,945,467) $ (5,538,475) $ (3,098,856)

Net loss        $ (2,796,621) $ (1,945,927) $  5,516,151  $ (3,104,088)


Net loss per
 share          $      (0.23) $      (0.24) $      (0.44) $      (0.40)

Weighted average
 number of shares
 used in the
 computation
 of loss per
 share            12,379,059     8,198,222    12,437,491     7,671,205